These results revealed that YY2 overexpression/anti‐PD‐L1 combinatorial therapy induces chromosome missegregation, pyroptosis, and the development of the immune microenvironment in tumor lesions, triggering CTL proliferation and activation while preventing their exhaustion. Here, YY2 is linked to neoplasm.